1. Miller MM, Revenis ME, Lai MM, et al. Risk and clinical course of retinopathy of prematurity in 78 infants of gestational age 22-25 weeks. J AAPOS. 2014;18(3):266-270.
2. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84(2):77-82.
3. Günay M, Topçuoğlu S, Çelik G, Gürsoy T. Prematüre retinopatisi: sıklık azalıyor mu? Zeynep Kamil Tip Bult. 2013;44(4):214-220.
4. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684-1694.
5. International Committee for the Classification of Retinopathy of Prematurity. The International classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991-999.
6. Drenser KA, Trese MT, Capone A Jr. Aggressive posterior retinopathy of prematurity. Retina. 2010;30(4 Suppl):S37-S40.
7. Good WV. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-248.
8. Harder BC, Schlichtenbrede FC, von Baltz S, et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;155(6):1119-1124.
9. Hwang CK, Hubbard GB, Hutchinson AK, et al. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015; 122(5):1008-1015.
10. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-615.
11. Fierson WM, Saunders RA, Good W, et al; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131(1):189-195.
12. Koç E, Baş AY, Özdek Ş, et al. Türkiye prematüre retinopatisi rehberi 2016. Available from http://www.neonatology.org.tr/wp-content/uploads/ 2016/12/premature_retinopatisi_rehberi.pdf
13. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of pre­maturity: results of the early treatment for retinopathy of pre­maturity randomized trial. Arch Ophthalmol. 2003;121(12):1684-1694.
14. Quinn GE, Dobson V, Barr CC, et al. Visual acuity of eyes af­ter vitrectomy for retinopathy of prematurity: follow-up at 5 1/2 years. Ophthalmology. 1996;103(4):595-600.
15. Repka MX, Tung B, Good WV, et al. Outcome of eyes developing retinal detachment during the early treatment for retinopathy of prematurity study (ETROP). Arch Ophthalmol. 2006;124(1):24-30.
16. Mintz-Hittner HA. Avastin as monotherapy for retinopathy of prematurity. J AAPOS. 2010;14(1):2-3.
17. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity. N Engl J Med. 2011;364(7):603-615.
18. Harder BC, Schlichtenbrede FC, von Baltz S, et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;155(6):1119-1124.
19. Alyamac SE, Comez A, Koçluk Y, et al. The process of retinal vascularization after anti-vegf treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica. 2016;236(3):139-147.
20. Spandau U, Tomic, Ewald U, et al. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol Acta Ophthalmol. 2013;91(2):170-175.
21. Yetik H, Gunay M, Sirop S, et al. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity-27 month follow-up results from Turkiye. Graefes Arch Clin Exp Ophthalmol. 2015;253(10):1677-1683.
22. Martínez-Castellanos MA, González-H León A, Romo-Aguas JC, Gonzalez-Gonzalez LA. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series. Graefes Arch Clin Exp Ophthalmol. 2020;258(4):767-772. doi:10.1007/s00417-020-04605-y
23. Nicoara SD, ?tefanut AC, Nascutzy C, et al. Regression rate following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis. Med Sci Monit. 2016;22:1192-1209.
24. Wallace DK, Kraker RT, Freedman SF, et al. Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135(6):654-656.
25. Çömez A, Karaküçük Y, Özmen MC, Çelemler P, Saygılı O. The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and type 1 retinopathy of prematurity. Eye (Lond). 2021;35(12):3302-3310.